Teleflex Incorporated

NYSE:TFX Stock Report

Market Cap: US$8.3b

Teleflex Valuation

Is TFX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TFX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TFX ($179.51) is trading below our estimate of fair value ($456.06)

Significantly Below Fair Value: TFX is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TFX?

Key metric: As TFX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TFX. This is calculated by dividing TFX's market cap by their current earnings.
What is TFX's PE Ratio?
PE Ratio35x
EarningsUS$238.01m
Market CapUS$8.34b

Price to Earnings Ratio vs Peers

How does TFX's PE Ratio compare to its peers?

The above table shows the PE ratio for TFX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average74.5x
MASI Masimo
116.5x30.0%US$9.2b
BAX Baxter International
123.2x40.5%US$14.9b
ITGR Integer Holdings
38.8x21.5%US$4.5b
ZBH Zimmer Biomet Holdings
19.6x7.9%US$21.3b
TFX Teleflex
35x22.8%US$8.3b

Price-To-Earnings vs Peers: TFX is good value based on its Price-To-Earnings Ratio (35x) compared to the peer average (74.5x).

Price to Earnings Ratio vs Industry

How does TFX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BDMD Baird Medical Investment Holdings
4.9xn/aUS$61.54m
MHUA Meihua International Medical Technologies
1xn/aUS$9.26m
PAVM PAVmed
0.5x-90.0%US$7.12m
RTSL Rapid Therapeutic Science Laboratories
0.5xn/aUS$30.38k
TFX 35.0xIndustry Avg. 34.8xNo. of Companies9PE020406080100+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TFX is expensive based on its Price-To-Earnings Ratio (35x) compared to the US Medical Equipment industry average (34.8x).

Price to Earnings Ratio vs Fair Ratio

What is TFX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TFX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio35x
Fair PE Ratio35.1x

Price-To-Earnings vs Fair Ratio: TFX is good value based on its Price-To-Earnings Ratio (35x) compared to the estimated Fair Price-To-Earnings Ratio (35.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TFX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$179.51
US$238.68
+33.0%
9.7%US$285.00US$200.00n/a12
Dec ’25US$192.85
US$245.01
+27.0%
8.7%US$285.00US$214.00n/a13
Nov ’25US$211.21
US$245.01
+16.0%
8.7%US$285.00US$214.00n/a13
Oct ’25US$245.13
US$258.65
+5.5%
6.3%US$285.00US$225.00n/a13
Sep ’25US$245.17
US$260.89
+6.4%
6.7%US$290.00US$225.00n/a14
Aug ’25US$235.95
US$253.88
+7.6%
7.7%US$285.00US$220.00n/a13
Jul ’25US$211.44
US$246.60
+16.6%
9.5%US$285.00US$210.00n/a14
Jun ’25US$209.07
US$245.23
+17.3%
10.9%US$285.00US$205.00n/a13
May ’25US$211.54
US$261.53
+23.6%
6.0%US$285.00US$225.00n/a14
Apr ’25US$222.88
US$263.31
+18.1%
5.5%US$285.00US$225.00n/a14
Mar ’25US$223.00
US$261.54
+17.3%
6.7%US$285.00US$211.00n/a14
Feb ’25US$247.65
US$263.46
+6.4%
7.4%US$285.00US$211.00n/a14
Jan ’25US$249.34
US$251.75
+1.0%
9.1%US$285.00US$211.00n/a14
Dec ’24US$227.67
US$239.67
+5.3%
8.9%US$285.00US$211.00US$192.8514
Nov ’24US$187.51
US$246.67
+31.6%
12.6%US$315.00US$210.00US$211.2114
Oct ’24US$196.41
US$259.31
+32.0%
12.2%US$315.00US$210.00US$245.1314
Sep ’24US$213.55
US$264.06
+23.7%
10.4%US$315.00US$211.00US$245.1714
Aug ’24US$249.28
US$268.14
+7.6%
10.9%US$330.00US$211.00US$235.9514
Jul ’24US$242.03
US$267.42
+10.5%
10.6%US$330.00US$211.00US$211.4414
Jun ’24US$233.77
US$271.53
+16.2%
10.6%US$330.00US$211.00US$209.0715
May ’24US$274.11
US$266.93
-2.6%
10.8%US$330.00US$211.00US$211.5414
Apr ’24US$253.31
US$260.07
+2.7%
11.1%US$330.00US$211.00US$222.8815
Mar ’24US$233.66
US$260.07
+11.3%
11.1%US$330.00US$211.00US$223.0015
Feb ’24US$250.18
US$258.00
+3.1%
12.8%US$330.00US$211.00US$247.6515
Jan ’24US$249.63
US$254.40
+1.9%
14.0%US$330.00US$211.00US$249.3415
Dec ’23US$244.80
US$247.93
+1.3%
14.8%US$330.00US$211.00US$227.6714

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 05:16
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/29
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Teleflex Incorporated is covered by 36 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Matthew TaylorBarclays
Craig BijouBofA Global Research